FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2185675674> ?p ?o ?g. }

• W2185675674 endingPage "8" @default.
• W2185675674 startingPage "311" @default.
• W2185675674 abstract "Bone metastases commonly occur in the course of malignant tumor disease. For many years, attempts have been made to identify factors for the management of cancer-induced skeletal complications. Nowadays, synthetic antiresorptive agents are considered to be indispensable for the treatment of cancer-related skeletal events, such as bone metastasis. The most common of these drugs are the bisphosphonates, which represent one of the most significant advances over the last 10 years in the field of supportive care and cancer. They are used for the treatment of cancer-induced hypercalcemia, for the prevention and treatment of postmenopausal osteoporosis, for patients with bone metastases secondary to breast cancer and multiple myeloma. A third-generation bisphosphonate, zolendronate, has been shown to minimize the destructive consequences of bone metastases and to exert a profound effect on tumor-induced osteolysis and tumor growth in bone. Zoledronate is already used for the treatment of hypercalcemia of malignancy, multiple myeloma-related osteolytic events and for patients with documented bone metastases from solid tumors in conjunction with standard antineoplastic therapy. The structure-function activity of the three generations of bisphosphonates developed to date, the in vitro models used for studying their effects on osteoclasts and osteoblasts, as well as the results of clinical trials obtained by the third generation bisphosphonate, zoledronic acid, are presented." @default.
• W2185675674 created "2016-06-24" @default.
• W2185675674 creator A5012410418 @default.
• W2185675674 creator A5022276978 @default.
• W2185675674 creator A5037481344 @default.
• W2185675674 date "2005-03-31" @default.
• W2185675674 modified "2023-09-25" @default.
• W2185675674 title "In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease." @default.
• W2185675674 cites W1532955823 @default.
• W2185675674 cites W157293976 @default.
• W2185675674 cites W1768011742 @default.
• W2185675674 cites W1937662086 @default.
• W2185675674 cites W1938796902 @default.
• W2185675674 cites W1970993628 @default.
• W2185675674 cites W1974903174 @default.
• W2185675674 cites W1975107690 @default.
• W2185675674 cites W1975805439 @default.
• W2185675674 cites W1976991071 @default.
• W2185675674 cites W1977203209 @default.
• W2185675674 cites W1978247877 @default.
• W2185675674 cites W1983583818 @default.
• W2185675674 cites W1987531304 @default.
• W2185675674 cites W1994414479 @default.
• W2185675674 cites W1995181451 @default.
• W2185675674 cites W2004135633 @default.
• W2185675674 cites W2006061245 @default.
• W2185675674 cites W2006825597 @default.
• W2185675674 cites W2006927651 @default.
• W2185675674 cites W2007569697 @default.
• W2185675674 cites W2014375336 @default.
• W2185675674 cites W2016308519 @default.
• W2185675674 cites W2019274861 @default.
• W2185675674 cites W2019964791 @default.
• W2185675674 cites W2027735110 @default.
• W2185675674 cites W2033586513 @default.
• W2185675674 cites W2036488551 @default.
• W2185675674 cites W2037935981 @default.
• W2185675674 cites W2038995854 @default.
• W2185675674 cites W2040874414 @default.
• W2185675674 cites W2044794329 @default.
• W2185675674 cites W2044868144 @default.
• W2185675674 cites W2049405916 @default.
• W2185675674 cites W2055606107 @default.
• W2185675674 cites W2058788578 @default.
• W2185675674 cites W2061276429 @default.
• W2185675674 cites W2062229770 @default.
• W2185675674 cites W2074890088 @default.
• W2185675674 cites W2098097319 @default.
• W2185675674 cites W2104550035 @default.
• W2185675674 cites W2106142458 @default.
• W2185675674 cites W2109529667 @default.
• W2185675674 cites W2120118174 @default.
• W2185675674 cites W2129296139 @default.
• W2185675674 cites W2138220544 @default.
• W2185675674 cites W2139347911 @default.
• W2185675674 cites W2144957471 @default.
• W2185675674 cites W2145741990 @default.
• W2185675674 cites W2146143139 @default.
• W2185675674 cites W2161690532 @default.
• W2185675674 cites W2314428698 @default.
• W2185675674 cites W2316096113 @default.
• W2185675674 cites W2325302070 @default.
• W2185675674 cites W2336678594 @default.
• W2185675674 cites W2341765369 @default.
• W2185675674 cites W2395496929 @default.
• W2185675674 cites W2415934797 @default.
• W2185675674 cites W2607028219 @default.
• W2185675674 cites W294732309 @default.
• W2185675674 cites W3205206586 @default.
• W2185675674 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15796191" @default.
• W2185675674 hasPublicationYear "2005" @default.
• W2185675674 type Work @default.
• W2185675674 sameAs 2185675674 @default.
• W2185675674 citedByCount "3" @default.
• W2185675674 countsByYear W21856756742023 @default.
• W2185675674 crossrefType "journal-article" @default.
• W2185675674 hasAuthorship W2185675674A5012410418 @default.
• W2185675674 hasAuthorship W2185675674A5022276978 @default.
• W2185675674 hasAuthorship W2185675674A5037481344 @default.
• W2185675674 hasConcept C121608353 @default.
• W2185675674 hasConcept C126322002 @default.
• W2185675674 hasConcept C141071460 @default.
• W2185675674 hasConcept C143998085 @default.
• W2185675674 hasConcept C150903083 @default.
• W2185675674 hasConcept C207001950 @default.
• W2185675674 hasConcept C2776169692 @default.
• W2185675674 hasConcept C2776326535 @default.
• W2185675674 hasConcept C2776364478 @default.
• W2185675674 hasConcept C2776541429 @default.
• W2185675674 hasConcept C2777251235 @default.
• W2185675674 hasConcept C2777783956 @default.
• W2185675674 hasConcept C2779399171 @default.
• W2185675674 hasConcept C2781282405 @default.
• W2185675674 hasConcept C530470458 @default.
• W2185675674 hasConcept C71924100 @default.
• W2185675674 hasConcept C86803240 @default.
• W2185675674 hasConceptScore W2185675674C121608353 @default.
• W2185675674 hasConceptScore W2185675674C126322002 @default.

• next